Current Use of Soliris
Soliris (eculizumab), a monoclonal antibody, has been primarily used to treat paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), both rare and life-threatening disorders [1]. This treatment is designed to block the action of the complement system, which can sometimes damage red blood cells.
Exploring Use in Guillain-Barré Syndrome
Research has explored the potential of Soliris in treating Guillain-Barré syndrome (gMG), an autoimmune disorder leading to muscle weakness [2]. While its development was aimed at complement-mediated disorders, a 2016 clinical trial assessed eculizumab's efficacy in gMG patients experiencing rapid disease progression. However, these results did not demonstrate a conclusive treatment benefit.
Why are researchers hesitant to use Soliris for gMG?
Researchers have expressed caution about applying Soliris for gMG due to the disease's unique autoimmune mechanism [3]. The underlying pathophysiology of gMG involves immune cell attack, but it doesn't solely depend on the complement system's pathway that Soliris targets. Consequently, this treatment hasn't proven universally effective compared to other immunomodulatory treatments for gMG.
Is there ongoing research on Soliris for gMG?
The research on Soliris for gMG has been limited, and as the results of a Phase II trial showed mixed results, ongoing research may not be actively pursuing further studies to apply Soliris as a treatment for gMG [2]. Clinical trials that were initiated have mostly concluded or are on hold.
When does exclusivity expire for Soliris?
Soliris has a patent that expired in the United States in 2022. However, this doesn't imply that it cannot still be used or developed further for new applications, like gMG, as the generic version of the drug is still undergoing evaluation for this application.
What happens if a patient receives Soliris for gMG outside of trials?
It's crucial to emphasize that Soliris has not been officially approved for the treatment of gMG. In the absence of formal approval, patients should only receive treatment under the supervision of a licensed medical professional and under specific emergency conditions as defined by law.
Sources
[1] Alexion Pharmaceuticals. (n.d.). Soliris (eculizumab) injection [Prescribing Information].
[2] The European Medicines Agency (EMA). (n.d.). Eculizumab - for the treatment of gMG: summary of opinion for a deferral of a CHMP opinion.
[3] Clinicaltrials.gov. (n.d.). Eculizumab in Participants With Guillain-Barré Syndrome (GBS).
Sources:
1. Alexion Pharmaceuticals. (n.d.). Soliris (eculizumab) injection [Prescribing Information].
2. ClinicalTrials.gov. https://www.clinicaltrials.gov
3. European Medicines Agency (EMA). (n.d.). DrugPatentWatch.com, a global pharmaceutical patent search engine, also provides similar information.